MA33071B1 - Compose a noyau condenses et son utilisation - Google Patents
Compose a noyau condenses et son utilisationInfo
- Publication number
- MA33071B1 MA33071B1 MA34132A MA34132A MA33071B1 MA 33071 B1 MA33071 B1 MA 33071B1 MA 34132 A MA34132 A MA 34132A MA 34132 A MA34132 A MA 34132A MA 33071 B1 MA33071 B1 MA 33071B1
- Authority
- MA
- Morocco
- Prior art keywords
- nucleus
- intensive
- composite
- diseases
- angiotensin
- Prior art date
Links
- 239000002131 composite material Substances 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention porte sur un nouveau composé représenté par la formule suivante, dans laquelle chaque symbole est tel que défini dans la description, ou sur un sel de ce composé, qui a une activité antagoniste des récepteurs de l'angiotensine II et une activité agoniste du récepteur ³ activé par les proliférateurs des peroxysomes, et qui est utile en tant qu'agent pour la prophylaxie ou le traitement de maladies circulatoires, telles que l'hypertension et similaire, et/ou de maladies métaboliques, telles que le diabète et similaire, et similaires.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009020720 | 2009-01-30 | ||
| PCT/JP2010/051651 WO2010087515A1 (fr) | 2009-01-30 | 2010-01-29 | Composé à noyaux condensés et son utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33071B1 true MA33071B1 (fr) | 2012-02-01 |
Family
ID=42026435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34132A MA33071B1 (fr) | 2009-01-30 | 2010-01-29 | Compose a noyau condenses et son utilisation |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US8592431B2 (fr) |
| EP (1) | EP2384327B1 (fr) |
| JP (2) | JP4892649B1 (fr) |
| KR (1) | KR20110113758A (fr) |
| CN (2) | CN102369205B (fr) |
| AR (1) | AR075344A1 (fr) |
| AU (1) | AU2010208863A1 (fr) |
| CA (1) | CA2750710C (fr) |
| CL (1) | CL2011001848A1 (fr) |
| CO (1) | CO6362011A2 (fr) |
| CR (1) | CR20110463A (fr) |
| CY (1) | CY1114530T1 (fr) |
| DK (1) | DK2384327T3 (fr) |
| DO (1) | DOP2011000249A (fr) |
| EA (1) | EA019823B1 (fr) |
| EC (1) | ECSP11011294A (fr) |
| ES (1) | ES2433225T3 (fr) |
| GE (1) | GEP20135961B (fr) |
| HR (1) | HRP20131017T1 (fr) |
| IL (1) | IL214283A0 (fr) |
| MA (1) | MA33071B1 (fr) |
| ME (1) | ME01621B (fr) |
| MX (1) | MX2011008058A (fr) |
| MY (1) | MY152946A (fr) |
| NZ (1) | NZ594606A (fr) |
| PE (1) | PE20120593A1 (fr) |
| PL (1) | PL2384327T3 (fr) |
| PT (1) | PT2384327E (fr) |
| RS (1) | RS53012B (fr) |
| SG (1) | SG173135A1 (fr) |
| SI (1) | SI2384327T1 (fr) |
| TN (1) | TN2011000368A1 (fr) |
| TW (2) | TWI468410B (fr) |
| UY (1) | UY32409A (fr) |
| WO (1) | WO2010087515A1 (fr) |
| ZA (1) | ZA201105867B (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102369205B (zh) * | 2009-01-30 | 2014-10-29 | 武田药品工业株式会社 | 稠环化合物和其用途 |
| DK2655375T3 (en) | 2010-12-23 | 2015-03-09 | Sanofi Sa | PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF |
| CZ304252B6 (cs) * | 2011-04-11 | 2014-01-29 | Zentiva, K. S. | Způsob výroby 2-ethoxy-1-((2´-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylátů a jejich převedení na azilsartan |
| ES2975263T3 (es) * | 2016-06-20 | 2024-07-04 | Novartis Ag | Formas cristalinas de un compuesto triazolopirimidínico |
| EP3687293A1 (fr) | 2017-09-26 | 2020-08-05 | Ecolab Usa Inc. | Compositions antimicrobiennes et virocides acides/anioniques et leurs utilisations |
| AU2019278015B2 (en) | 2018-05-31 | 2024-10-03 | Hua Medicine (Shanghai) Ltd. | Pharmaceutical combination, composition, and combination formulation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| WO2020205560A1 (fr) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Composés sulfonylamides utilisés comme inhibiteurs de la cdk2 |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223469A1 (fr) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer |
| CA3150681A1 (fr) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Composes imidazolyl-pyrimidinylamines utilises comme inhibiteurs de la cdk2 |
| US11851426B2 (en) | 2019-10-11 | 2023-12-26 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN112745319B (zh) * | 2019-10-30 | 2022-06-17 | 中国科学院上海药物研究所 | 一类取代三环结构的化合物、其制备方法及用途 |
| AU2020408331B2 (en) | 2019-12-16 | 2023-12-14 | Ecolab Usa Inc. | Anionic surfactant impact on virucidal efficacy |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2672892B1 (fr) * | 1991-02-20 | 1994-01-14 | Synthelabo | Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique. |
| US5472967A (en) | 1991-02-20 | 1995-12-05 | Synthelabo | 4-pyrimidinone derivatives their preparation and their application in therapy |
| IL102183A (en) | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them |
| TW251288B (fr) * | 1991-06-27 | 1995-07-11 | Takeda Dharm Industry Co Ltd | |
| IT1250749B (it) * | 1991-08-02 | 1995-04-21 | Luso Farmaco Inst | Composti eterociclici ad attivita' a ii antagonista |
| FR2687677B1 (fr) * | 1992-02-24 | 1996-10-11 | Union Pharma Scient Appl | Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant. |
| US5389632A (en) | 1992-02-24 | 1995-02-14 | Laboratoires Upsa | Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists |
| US5387747A (en) | 1992-02-24 | 1995-02-07 | Laboratoires Upsa | Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present |
| IT1263804B (it) | 1993-01-22 | 1996-09-03 | Luso Farmaco Inst | Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista |
| GB9406573D0 (en) | 1994-03-31 | 1994-05-25 | Merck Sharp & Dohme | Medicaments |
| AU725689B2 (en) | 1995-06-07 | 2000-10-19 | G.D. Searle & Co. | Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of congestive heart failure |
| KR19990022723A (ko) | 1995-06-07 | 1999-03-25 | 윌리암스 로저 에이 | 울혈성심부전의 치료를 위한 스피로노락톤 및 앤지오텐신 ii 길 항제 복합요법 |
| WO1996040255A2 (fr) | 1995-06-07 | 1996-12-19 | G.D. Searle & Co. | Procede de traitement de la fibrose cardiaque par une combinaison therapeutique d'un antagoniste de l'angiotensine ii et d'un antagoniste de l'aldosterone epoxy-steroide |
| WO1996040256A1 (fr) | 1995-06-07 | 1996-12-19 | G.D. Searle & Co. | Procede de traitement de la cardiofibrose avec une combinaison de spironolactone et d'un antagoniste de l'angiotensive ii |
| FR2812876B1 (fr) | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| SE0101579D0 (sv) | 2001-05-04 | 2001-05-04 | Astrazeneca Ab | New compounds |
| US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| TW200418835A (en) | 2003-01-24 | 2004-10-01 | Tanabe Seiyaku Co | A pyrazolopyrimidine compound and a process for preparing the same |
| WO2005020984A2 (fr) | 2003-08-29 | 2005-03-10 | Aaipharma Inc. | Methode de reduction du stress oxydatif |
| JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
| CA2569016C (fr) | 2004-06-02 | 2012-11-27 | Takeda Pharmaceutical Company Limited | Compose heterocyclique fusionne |
| US20050288272A1 (en) | 2004-06-23 | 2005-12-29 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists |
| CN1972679B (zh) | 2004-06-23 | 2010-07-28 | 索尔瓦药物有限公司 | 包括nep-抑制剂、内源性内皮缩血管肽产生系统抑制剂和at1受体拮抗剂的药物组合物 |
| CA2616150A1 (fr) | 2005-07-27 | 2007-02-01 | Talia Weinstein | Inhibition du systeme renine-angiotensine pour le traitement de pathologies renales, vasculaires et cartilagineuses |
| WO2007053406A1 (fr) | 2005-10-28 | 2007-05-10 | Novartis Ag | Combinaison de composes organiques hypotenseurs et hypocholesterolemiant |
| WO2007051007A2 (fr) | 2005-10-28 | 2007-05-03 | Novartis Ag | Combinaison de composes organiques |
| US20080064871A1 (en) | 2006-05-26 | 2008-03-13 | Japan Tobacco Inc. | Production Method of Nitrogen-Containing Fused Ring Compounds |
| EP2078205A2 (fr) | 2006-11-09 | 2009-07-15 | Ore Pharmaceuticals Inc. | Procédés de dépistage et de traitement du cancer du sein |
| US20090012052A1 (en) | 2006-11-09 | 2009-01-08 | Ore Pharmaceuticals Inc. | Method for treating er+ breast cancer |
| KR20090085117A (ko) * | 2006-11-24 | 2009-08-06 | 다케다 야쿠힌 고교 가부시키가이샤 | 헤테로모노시클릭 화합물 및 이의 용도 |
| JPWO2008143262A1 (ja) * | 2007-05-21 | 2010-08-12 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| EP2203057A4 (fr) | 2007-09-20 | 2010-09-29 | Univ Rochester | Procédés et compositions pour le traitement ou la prévention d'états inflammatoires |
| AU2009228765B2 (en) | 2008-03-24 | 2012-05-31 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
| CA2723372A1 (fr) | 2008-05-05 | 2009-11-12 | University Of Rochester | Procedes et compositions pour le traitement ou la prevention d'une remodelisation cardiaque pathologique et d'une insuffisance cardiaque |
| CN102369205B (zh) * | 2009-01-30 | 2014-10-29 | 武田药品工业株式会社 | 稠环化合物和其用途 |
-
2010
- 2010-01-29 CN CN201080014441.7A patent/CN102369205B/zh not_active Expired - Fee Related
- 2010-01-29 PT PT107035321T patent/PT2384327E/pt unknown
- 2010-01-29 MA MA34132A patent/MA33071B1/fr unknown
- 2010-01-29 ES ES10703532T patent/ES2433225T3/es active Active
- 2010-01-29 PE PE2011001418A patent/PE20120593A1/es not_active Application Discontinuation
- 2010-01-29 AR ARP100100240A patent/AR075344A1/es unknown
- 2010-01-29 PL PL10703532T patent/PL2384327T3/pl unknown
- 2010-01-29 JP JP2011525329A patent/JP4892649B1/ja not_active Expired - Fee Related
- 2010-01-29 US US13/146,989 patent/US8592431B2/en not_active Expired - Fee Related
- 2010-01-29 UY UY0001032409A patent/UY32409A/es not_active Application Discontinuation
- 2010-01-29 TW TW99102537A patent/TWI468410B/zh not_active IP Right Cessation
- 2010-01-29 MX MX2011008058A patent/MX2011008058A/es active IP Right Grant
- 2010-01-29 ME MEP-2013-131A patent/ME01621B/me unknown
- 2010-01-29 SG SG2011053741A patent/SG173135A1/en unknown
- 2010-01-29 DK DK10703532.1T patent/DK2384327T3/da active
- 2010-01-29 WO PCT/JP2010/051651 patent/WO2010087515A1/fr not_active Ceased
- 2010-01-29 KR KR1020117020049A patent/KR20110113758A/ko not_active Withdrawn
- 2010-01-29 CN CN201310750040.3A patent/CN103788097B/zh not_active Expired - Fee Related
- 2010-01-29 HR HRP20131017AT patent/HRP20131017T1/hr unknown
- 2010-01-29 NZ NZ594606A patent/NZ594606A/xx not_active IP Right Cessation
- 2010-01-29 SI SI201030403T patent/SI2384327T1/sl unknown
- 2010-01-29 AU AU2010208863A patent/AU2010208863A1/en not_active Abandoned
- 2010-01-29 EA EA201101138A patent/EA019823B1/ru not_active IP Right Cessation
- 2010-01-29 US US12/696,147 patent/US8283353B2/en not_active Expired - Fee Related
- 2010-01-29 MY MYPI2011003554 patent/MY152946A/en unknown
- 2010-01-29 EP EP10703532.1A patent/EP2384327B1/fr active Active
- 2010-01-29 TW TW103125956A patent/TW201444848A/zh unknown
- 2010-01-29 GE GEAP201012358A patent/GEP20135961B/en unknown
- 2010-01-29 CA CA2750710A patent/CA2750710C/fr not_active Expired - Fee Related
- 2010-01-29 RS RS20130472A patent/RS53012B/sr unknown
-
2011
- 2011-06-30 JP JP2011146858A patent/JP5676379B2/ja not_active Expired - Fee Related
- 2011-07-25 IL IL214283A patent/IL214283A0/en unknown
- 2011-07-27 TN TN2011000368A patent/TN2011000368A1/fr unknown
- 2011-07-29 CL CL2011001848A patent/CL2011001848A1/es unknown
- 2011-07-29 DO DO2011000249A patent/DOP2011000249A/es unknown
- 2011-08-09 US US13/205,967 patent/US8921379B2/en not_active Expired - Fee Related
- 2011-08-11 ZA ZA2011/05867A patent/ZA201105867B/en unknown
- 2011-08-26 CR CR20110463A patent/CR20110463A/es unknown
- 2011-08-29 CO CO11109923A patent/CO6362011A2/es active IP Right Grant
- 2011-08-30 EC EC2011011294A patent/ECSP11011294A/es unknown
-
2013
- 2013-10-22 US US14/059,868 patent/US9115136B2/en not_active Expired - Fee Related
- 2013-10-25 CY CY20131100941T patent/CY1114530T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33071B1 (fr) | Compose a noyau condenses et son utilisation | |
| MA31084B1 (fr) | Derives de piperidine agonistes de gpcr | |
| MA30528B1 (fr) | Antagoniste du recepteur il-8. | |
| MA32614B1 (fr) | Compositions therapeutiques contenant du macitentan | |
| MA31189B1 (fr) | Composés à cycles fusionnés utiles en tant qu'agonistes partiels de ppar-gamma | |
| MA46286B1 (fr) | Dérivé de pyrazolopyridine ayant un effet agoniste du récepteur glp-1 | |
| EA200701705A1 (ru) | Антагонисты рецепторы глюкагона, получение и терапевтическое применение | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| MA32903B1 (fr) | Inhibiteurs de proteine-kinases | |
| EP2324029A4 (fr) | Inhibiteurs hétérocyliques des récepteurs de l'histamine destinés au traitement d'une maladie | |
| BRPI0714315B8 (pt) | arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende | |
| MA33304B1 (fr) | Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase | |
| MA33178B1 (fr) | Pipéridines substituées comme antagonistes de ccr3 | |
| TN2014000243A1 (fr) | Benzopyrannes nouveaux, compositions les contenant et leurs utilisations | |
| MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 | |
| MA32171B1 (fr) | Compose heterocyclique | |
| EA201070535A1 (ru) | Новые агонисты глюкокортикоидных рецепторов | |
| MA30556B1 (fr) | COMPOSES A BASE DE DIALKYLPHENYLE AYANT UNE ACTIVITE AGONISTE DU RECEPTEUR ADRENERGIQUE ß2 ET ANTAGONISTE DU RECEPTEUR MUSCARINIQUE. | |
| CY1110922T1 (el) | Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις | |
| DK1735278T3 (da) | Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser | |
| TNSN08337A1 (fr) | Piperidinoylpyrrolidines agonistes du recepteur de melanocortine de type 4 | |
| DK2081572T3 (da) | Benzimidazol-cannabinoid-agonister med en substitueret heterocyklisk gruppe | |
| MA33836B1 (fr) | Compositions pharmaceutiques contenant des ligands des récepteurs sigma | |
| ATE552246T1 (de) | Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten | |
| MA29541B1 (fr) | Composes benzimidazole-carboxamide utilises comme agonistes du recepteur 5-ht4 |